Local Consolidative Therapy, Oligoprogression Management, and Regimen Selection in EGFR-Mutated NSCLC

Dr. Herbst asks about clinical trial data combining local therapy with targeted therapy in EGFR-mutated NSCLC. Dr. Kareff references the NorthStar trial, which evaluated local consolidative therapy, primarily radiation, in patients on single-agent osimertinib with evidence of progression or need for local intervention, demonstrating PFS improvements with this combined approach. He notes a critical interpretive limitation: NorthStar enrolled patients on osimertinib monotherapy, and extrapolating these findings to patients receiving FLAURA2 or MARIPOSA-based regimens requires caution given the different disease contexts and patient populations. He uses NorthStar data selectively when discussing oligoprogression management with patients who have had durable disease control on osimertinib monotherapy and are now considering consolidation.

For the clinical case patient with three small asymptomatic brain metastases, Dr. Herbst states his preference for FLAURA2 (osimertinib plus carboplatin-pemetrexed), citing the importance of CNS-penetrant osimertinib combined with chemotherapy for more advanced systemic disease, while noting any of the intensified regimens could be appropriate. Dr. Kareff agrees with this approach and adds that for patients with small CNS lesions as the dominant or only site of metastatic disease, the amivantamab-lazertinib combination is also highly attractive given its CNS efficacy signal in MARIPOSA. For this specific case with an adrenal metastasis, he would also be comfortable with subcutaneous amivantamab plus oral lazertinib.

Dr. Herbst emphasizes that given this patient's concerns about cognition and independence, minimizing brain radiation is a priority; the intracranial response rates with the intensified systemic regimens are high enough to justify initial management with systemic therapy alone, with radiation reserved for cases where systemic CNS control is inadequate.